>> Kenvue's quarterly figures -- Fresh breath thanks to Listerine? <<
Shares of Listerine mouthwash maker Kenvue rise 13.5 percent to $20.65 in morning trading - biggest percentage gain in the stock if earnings hold.
KVUE beats Q2 estimates, thanks largely to better-than-expected sales of essential health products.
The division reported Q2 sales of $1.26 billion, slightly above analysts' average estimate of $1.24 billion - LSEG data.
Co reported Q2 sales of $4.00 billion, beating analysts' estimates of $3.94 billion
The company reported organic sales growth of 1.5% versus analysts' consensus expectations of a 1.1% decline - brokerage J.P. Morgan. The brokerage says KVUE's organic revenue growth on better-than-expected volumes "was a relief to investors who we believe were expecting a weak print"
The company posted adj. earnings of 32 cents/shr, beating estimates by 4 cents.
KVUE, which came to market last year after its spinoff from Johnson & Johnson, was down 15.5% at the close.
He still has the share, from the spin-off of $JNJ (+0,13 %) ?